Cardiomyopathy
Conditions
Interventions
Verasonic Vantage 128TM ultrasound system
Sponsors
Maastricht Universitair Medisch Centrum +
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:For group 1 (G+P+) and 2 (G-P+)Age >18 years;Patients with DCM according to the latest guidelines of the European Society of Cardiology (ESC);Recent (within 6 months) CMR including LGE contrast imaging;Patients underwent complete genetic testing according to the latest standards of routine clinical care (but only in group 1 a genetic mutation has been identified).For group 3 (G+P-)Age >18 years;Left ventricular ejection fraction >50%;Recent (within 6 months) CMR including LGE contrast imaging;Presence of the familial genetic mutation is confirmed by genetic testing in routine clinical care.For group 4 (G-P-)Age >18 years;Left ventricular ejection fraction >50%;No medical history of cardiac disease;No family history of sudden cardiac death and/or cardiomyopathy.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study:For all groupsPresence of a cardiac device (ICD, PM, or CRT-D);Patients with unstable heart failure;Pregnancy before study participation;Unwillingness to participate or unable to give written informed consent (due to language barrier or severe intellectual disability).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure of the shear wave measurement will be shear wave propagation speed. This is a numerical outcome measure that has been shown in other studies to correlate with tissue stiffness.In Work Package 1 (WP1), the goal is to assess whether the numerical shear wave values correspond to the presence of LGE (Yes/No) on CMR. | — |
Secondary
| Measure | Time frame |
|---|---|
| In Work Package 3 (WP3), the prognostic value of shear waves in asymptomatic family members will be examined.A cut-off value will be determined using cubic spline analysis. The aim is to assess whether an abnormal shear wave value is predictive of the development of the DCM phenotype.Furthermore, All other clinical variables will be re-used from the mCMP registry (METC 21-017), where all participants are already included. Specifically relevant is the information on cardiac function during follow-up. Additional data from longitudinal echocardiography to diagnose phenotype development in G+P- family members is collected as part of the mCMP registry. | — |
Countries
Netherlands
Contacts
Public ContactM.F.G.H.M Venner
Maastricht Universitair Medisch Centrum +
Outcome results
None listed